Search
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox. … [A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002.
Hydroxycitronellal
go.drugbank.com/drugs/DB14187ApprovedHydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain
Abametapir
go.drugbank.com/drugs/DB11932Approved[A216178] Abametapir was first approved for use in the United States under the brand name Xeglyze on July 27, 2020.[L15163] … [A216178] Abemetapir is an inhibitor of these metalloproteinase enzymes, and the first topical pediculicide to take advantage of this novel target.
Eplontersen
go.drugbank.com/drugs/DB16199ApprovedInvestigational[A262990] On December 21, 2023, the FDA approved eplontersen under the brand name WAINUA for the treatment of adult polyneuropathy of hereditary transthyretin-mediated amyloidosis. … analysis from the Phase 3 NEURO-TTRansform study, where a consistent improvement in the Neuropathy Impairment Score +7 (mNIS+7) and the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN
Turoctocog alfa pegol
go.drugbank.com/drugs/DB14738ApprovedInvestigationalNovo Nordisk's brand name Esperoct (turoctocog alfa pegol, N8-GP) was approved by the US FDA on February 19, 2019. … It was developed by Novo Nordisk and approved by the US FDA on October 16, 2013 [L1104].
Products: ESPEROCT 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET, ESPEROCT 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADETTick-borne encephalitis vaccine (whole virus, inactivated)
go.drugbank.com/drugs/DB16611ApprovedInvestigational[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … [A237520] Due to a paucity of effective safe and effective acute therapeutic agents, vaccination remains the most important defence against TBE in endemic areas.
Selinexor
go.drugbank.com/drugs/DB11942ApprovedInvestigational[L10145] The FDA approved Selinexor in June 2019. … [L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant.
Lesinurad
go.drugbank.com/drugs/DB11560ApprovedWithdrawnIn August 2017, a combination oral therapy consisting of lesinurad and [DB00437] was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout.
Sonidegib
go.drugbank.com/drugs/DB09143ApprovedInvestigationalSonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma.
Liothyronine
go.drugbank.com/drugs/DB00279ApprovedInvestigationalVet approved[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578]